Archive \ Volume.16 2025 Issue 4

Measuring Pharmacy Artificial Intelligence by Avoided Harm, Recovered Time, and Better Decisions

, ,
  1. Department of Pharmacy AI Outcome Measurement, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
  2. Department of Value-Based AI Assessment, Faculty of Pharmacy, University of Porto, Porto, Portugal.

Abstract

Artificial intelligence in pharmacy is often evaluated through discrimination, accuracy, alert yield, or task completion, yet these measures do not establish whether medication-related harm was avoided, professional time was genuinely recovered, or decisions became better. This article proposes a non-empirical value-evaluation framework for connecting technical performance to pharmacy-practice consequences without treating any single metric as sufficient. Value is defined as attributable, net, distributed, and sustained benefit relative to a specified medication-use problem, comparator, perspective, and time horizon. The framework separates seven evaluative layers: baseline need, technical fitness, pharmacy-task performance, human–AI and workflow interaction, consequence measurement, attribution, and net value. Three consequence domains are distinguished. Avoided harm requires evidence linking an AI signal to professional review, action, changed medication use, and a credible counterfactual clinical consequence. Recovered time requires deduction of verification, correction, training, maintenance, and coordination work, followed by assessment of how released capacity is used. Better decisions require evaluation of interpretation, uncertainty handling, appropriateness, timeliness, and final action rather than agreement with AI alone. Validation should combine task-specific performance studies, workflow observation, human-factors assessment, comparative outcome designs, economic evaluation, subgroup analysis, and postimplementation monitoring. The proposed framework does not supply universal thresholds, combine heterogeneous outcomes into a single score, or establish safety, cost-effectiveness, regulatory acceptability, or deployment readiness. Its original contribution is an evidence-bounded architecture for designing, interpreting, and governing pharmacy-AI value claims.


Downloads: 26
Views: 97

How to cite:
Vancouver
Rodrigues A, Martins T, Lopes B. Measuring Pharmacy Artificial Intelligence by Avoided Harm, Recovered Time, and Better Decisions. Arch Pharm Pract. 2025;16(4):64-72. https://doi.org/10.51847/zwjUAgneRK
APA
Rodrigues, A., Martins, T., & Lopes, B. (2025). Measuring Pharmacy Artificial Intelligence by Avoided Harm, Recovered Time, and Better Decisions. Archives of Pharmacy Practice, 16(4), 64-72. https://doi.org/10.51847/zwjUAgneRK

Download Citation
References
  1. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019;17(1):195. doi:10.1186/s12916-019-1426-2
  2. Nagendran M, Chen Y, Lovejoy CA, Gordon AC, Komorowski M, Harvey H, et al. Artificial intelligence versus clinicians: Systematic review of design, reporting standards, and claims of deep learning studies. BMJ. 2020;368. doi:10.1136/bmj.m689
  3. Wiens J, Saria S, Sendak M, Ghassemi M, Liu VX, Doshi-Velez F, et al. Do no harm: A roadmap for responsible machine learning for health care. Nat Med. 2019;25(9):1337-40. doi:10.1038/s41591-019-0548-6
  4. Vollmer S, Mateen BA, Bohner G, Király FJ, Ghani R, Jonsson P, et al. Machine learning and artificial intelligence research for patient benefit: 20 critical questions on transparency, replicability, ethics, and effectiveness. BMJ. 2020;368. doi:10.1136/bmj.l6927
  5. Liu X, Faes L, Kale AU, Wagner SK, Fu DJ, Bruynseels A, et al. A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: A systematic review and meta-analysis. Lancet Digit Health. 2019;1(6). doi:10.1016/S2589-7500(19)30123-2
  6. Hatzimanolis J, Riley B, El-Den S, Aslani P, Zhou J, Chaar BB. Applications of artificial intelligence in current pharmacy practice: A scoping review. Res Social Adm Pharm. 2025;21(3):134-41. doi:10.1016/j.sapharm.2024.12.007
  7. Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care—a health economics approach: An ISPOR Special Task Force report [3]. Value Health. 2018;21(2):131-9. doi:10.1016/j.jval.2017.12.007
  8. Mathews SC, McShea MJ, Hanley CL, Ravitz A, Labrique AB, Cohen AB. Digital health: A path to validation. NPJ Digit Med. 2019;2(1):38. doi:10.1038/s41746-019-0111-3
  9. Greenhalgh T, Wherton J, Papoutsi C, Lynch J, Hughes G, A’Court C, et al. Beyond adoption: A new framework for theorizing and evaluating nonadoption, abandonment, and challenges to the scale-up, spread, and sustainability of health and care technologies. J Med Internet Res. 2017;19(11). doi:10.2196/jmir.8775
  10. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3-9. doi:10.1016/j.jval.2021.11.1351
  11. Graafsma J, Murphy RM, van de Garde EMW, Karapinar-Çarkit F, Derijks HJ, Hoge RHL, et al. The use of artificial intelligence to optimize medication alerts generated by clinical decision support systems: A scoping review. J Am Med Inform Assoc. 2024;31(6):1411-22. doi:10.1093/jamia/ocae076
  12. Rozenblum R, Rodriguez-Monguio R, Volk LA, Forsythe KJ, Myers S, McGurrin M, et al. Using a machine learning system to identify and prevent medication prescribing errors: A clinical and cost analysis evaluation. Jt Comm J Qual Patient Saf. 2020;46(1):3-10. doi:10.1016/j.jcjq.2019.09.008
  13. Levivien C, Cavagna P, Grah A, Buronfosse A, Courseau R, Bézie Y, et al. Assessment of a hybrid decision support system using machine learning with artificial intelligence to safely rule out prescriptions from medication review in daily practice. Int J Clin Pharm. 2022;44(2):459-65. doi:10.1007/s11096-021-01366-4
  14. Elliott RA, Camacho E, Jankovic D, Sculpher MJ, Faria R. Economic analysis of the prevalence and clinical and economic burden of medication error in England. BMJ Qual Saf. 2021;30(2):96-105. doi:10.1136/bmjqs-2019-010206
  15. Kiani A, Uyumazturk B, Rajpurkar P, Wang A, Gao R, Jones E, et al. Impact of a deep learning assistant on the histopathologic classification of liver cancer. NPJ Digit Med. 2020;3(1):23. doi:10.1038/s41746-020-0232-8
  16. Tschandl P, Rinner C, Apalla Z, Argenziano G, Codella N, Halpern A, et al. Human–computer collaboration for skin cancer recognition. Nat Med. 2020;26(8):1229-34. doi:10.1038/s41591-020-0942-0
  17. Gaube S, Suresh H, Raue M, Merritt A, Berkowitz SJ, Lermer E, et al. Do as AI say: Susceptibility in deployment of clinical decision-aids. NPJ Digit Med. 2021;4(1):31. doi:10.1038/s41746-021-00385-9
  18. Goh E, Gallo R, Hom J, Strong E, Weng Y, Kerman H, et al. Large language model influence on diagnostic reasoning: A randomized clinical trial. JAMA Netw Open. 2024;7(10). doi:10.1001/jamanetworkopen.2024.40969
  19. Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56. doi:10.1038/s41591-018-0300-7
  20. Vasey B, Nagendran M, Campbell B, Clifton DA, Collins GS, Denaxas S, et al. Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI. Nat Med. 2022;28(5):924-33. doi:10.1038/s41591-022-01772-9
  21. Liu X, Cruz Rivera S, Moher D, Calvert MJ, Denniston AK, Chan AW, et al. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: The CONSORT-AI extension. Nat Med. 2020;26(9):1364-74. doi:10.1038/s41591-020-1034-x
  22. Cruz Rivera S, Liu X, Chan AW, Denniston AK, Calvert MJ, Ashrafian H, et al. Guidelines for clinical trial protocols for interventions involving artificial intelligence: The SPIRIT-AI extension. Nat Med. 2020;26(9):1351-63. doi:10.1038/s41591-020-1037-7
  23. Plana D, Shung DL, Grimshaw AA, Saraf A, Sung JJY, Kann BH. Randomized clinical trials of machine learning interventions in health care: A systematic review. JAMA Netw Open. 2022;5(9). doi:10.1001/jamanetworkopen.2022.33946
  24. Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al. A new framework for developing and evaluating complex interventions: Update of Medical Research Council guidance. BMJ. 2021;374. doi:10.1136/bmj.n2061
  25. Lopez Bernal J, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: A tutorial. Int J Epidemiol. 2017;46(1):348-55. doi:10.1093/ije/dyw098
  26. Futoma J, Simons M, Panch T, Doshi-Velez F, Celi LA. The myth of generalisability in clinical research and machine learning in health care. Lancet Digit Health. 2020;2(9). doi:10.1016/S2589-7500(20)30186-2
  27. van der Vegt AH, Scott IA, Dermawan K, Schnetler RJ, Kalke VR, Lane PJ. Implementation frameworks for end-to-end clinical AI: Derivation of the SALIENT framework. J Am Med Inform Assoc. 2023;30(9):1503-15. doi:10.1093/jamia/ocad088
  28. Shaw J, Agarwal P, Desveaux L, Palma DC, Stamenova V, Jamieson T, et al. Beyond “implementation”: Digital health innovation and service design. NPJ Digit Med. 2018;1(1):48. doi:10.1038/s41746-018-0059-8
  29. Farah L, Borget I, Martelli N, Vallee A. Suitability of the current health technology assessment of innovative artificial intelligence-based medical devices: Scoping literature review. J Med Internet Res. 2024;26. doi:10.2196/51514
  30. Parikh RB, Obermeyer Z, Navathe AS. Regulation of predictive analytics in medicine. Science. 2019;363(6429):810-2. doi:10.1126/science.aaw0029
  31. Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366(6464):447-53. doi:10.1126/science.aax2342
  32. Ghassemi M, Oakden-Rayner L, Beam AL. The false hope of current approaches to explainable artificial intelligence in health care. Lancet Digit Health. 2021;3(11). doi:10.1016/S2589-7500(21)00208-9
  33. Seyyed-Kalantari L, Zhang H, McDermott MBA, Chen IY, Ghassemi M. Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in underserved patient populations. Nat Med. 2021;27(12):2176-82. doi:10.1038/s41591-021-01595-0
  34. Cabitza F, Rasoini R, Gensini GF. Unintended consequences of machine learning in medicine. JAMA. 2017;318(6):517-8. doi:10.1001/jama.2017.7797

 

 


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.